NDA 203414 · Takeda Pharms USA
Kazano
Alogliptin Benzoate, Metformin Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Jan 25, 2013
Approved uses
3
Original approval plus efficacy supplements
Registered trials
6
1 Phase 3, 0 recruiting
FAERS reports
140
62 serious, 4 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmia's. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (greater than 5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally greater than 5 mcg/mL [see Warnings and Precautions (5.1) ]. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study...
What it is approved for
From the label in effect Aug 25, 2026.
Alogliptin and metformin HCl tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin and metformin HCl tablets are a combination of alogliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Should not be used in patients with type 1 diabetes mellitus. ( 1 ) Limitations of Use Alogliptin and metformin HCl tablets should not recommended for use in patients with type 1 diabetes mellitus.
Mechanism: Alogliptin and Metformin HCl Alogliptin and metformin HCl tablets combines two antihyperglycemic agents with complementary and distinct mechanisms of action to improve glycemic control in patients with type 2 diabetes mellitus: alogliptin, a selective inhibitor of DPP-4, and metformin HCl, a member of the biguanide class. Alogliptin Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals. These hormones cause insulin release...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 27, 2023 Supplement 16 · Efficacy LabelMedication GuideLetter
- Apr 5, 2016 Supplement 3 · Efficacy LabelLetter
- Jan 25, 2013 Original approval · Type 4 - New Combination ReviewSummary ReviewLetter
2 products under this application
- KAZANO · ALOGLIPTIN BENZOATE EQ 12.5MG BASE; METFORMIN HYDROCHLORIDE 500MG · TABLET, ORAL · Prescription
- KAZANO · ALOGLIPTIN BENZOATE EQ 12.5MG BASE; METFORMIN HYDROCHLORIDE 1GM · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Alogliptin Benzoate" as an intervention, any sponsor and status, largest first.
- Phase 3 Alogliptin Pediatric StudyPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT02856113 · 152 participants · Start Oct 14, 2016 · Primary completion Aug 6, 2021
Drug: Alogliptin Benzoate; Placebo · For: Diabetes Mellitus, Type 2
Sites: Little Rock, Arkansas; Los Angeles, California; Palmdale, California · 67 sites in all
Fourth People's Hospital of ShenyangAcademic, hospital or other
NCT02798172 · 81 participants · Start May 2014 · Primary completion Aug 2015
Drug: Alogliptin and Metformin · For: Diabetes Mellitus, Type 2
Yonsei UniversityAcademic, hospital or other
NCT03950505 · 60 participants (planned) · Start May 29, 2020 · Primary completion Dec 2020
Drug: Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks · For: Non-alcoholic Steatohepatitis; Type2 Diabetes
Sites: Seoul, South Korea
CelltrionIndustry
NCT05363592 · 48 participants · Start Jun 25, 2022 · Primary completion Jul 5, 2022
Drug: CT-L01 12.5/500 mg; Alogliptin Benzoate 12.5 mg and 1 more · For: Healthy
Sites: Daejeon, South Korea
CelltrionIndustry
NCT05363384 · 48 participants · Start Jun 11, 2022 · Primary completion Jun 21, 2022
Drug: CT-L01; Alogliptin Benzoate 25 mg and 1 more · For: Healthy
Sites: Daejeon, South Korea
CelltrionIndustry
NCT05364164 · 24 participants · Start Jul 9, 2022 · Primary completion Jul 19, 2022
Drug: CT-L01 12.5/1,000 mg; CT-L01 12.5/1,000 mg · For: Healthy
Sites: Daejeon, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea17
- nausea14
- drug ineffective12
- blood pressure increased10
- dyspnoea10
- heart rate increased8
- hypertension8
- pneumonia8
- blood glucose increased7
- chest pain7
- anxiety6
- back pain6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 3 |
| 2014 | 32 |
| 2015 | 21 |
| 2016 | 21 |
| 2017 | 7 |
| 2018 | 5 |
| 2019 | 7 |
| 2020 | 10 |
| 2021 | 1 |
| 2022 | 12 |
| 2023 | 4 |
| 2024 | 9 |
| 2025 | 5 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Kazano (Alogliptin Benz/Metformin HCl)
2024 spending
$27K
Beneficiaries
41
63 claims
Per beneficiary
$656
$5.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $242,607 |
| 2021 | $122,548 |
| 2022 | $108,755 |
| 2023 | $111,510 |
| 2024 | $26,879 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study.
Nakamura Y, Inagaki M, Shimizu T, et al. · Nephron Clin Pract 2013 · Clinical Trial
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.